Novavax (NVAX) Marked As A Dead Cat Bounce Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Novavax ( NVAX) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Novavax as such a stock due to the following factors:

  • NVAX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.6 million.
  • NVAX has traded 1.1 million shares today.
  • NVAX is up 3.4% today.
  • NVAX was down 7.9% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in NVAX with the Ticky from Trade-Ideas. See the FREE profile for NVAX NOW at Trade-Ideas

More details on NVAX:

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing recombinant protein nanoparticle vaccines and adjuvants. Currently there are 3 analysts that rate Novavax a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Novavax has been 4.0 million shares per day over the past 30 days. Novavax has a market cap of $1.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.04 and a short float of 13.5% with 8.62 days to cover. Shares are down 17.6% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering